Brief: Carsgen Therapeutics Says Ct041 Receives Approval From NMPA To Initiate Phase II Clinical Trial In China
03/03/2022 01:08
March 3 (Reuters) - CARsgen Therapeutics Holdings Ltd
2171.HK :
* CT041 RECEIVES APPROVAL FROM NMPA TO INITIATE PHASE II
CLINICAL
TRIAL IN CHINA FOR TREATMENT OF ADVANCED GASTRIC JUNCTION CANCER
Further company coverage: 2171.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer